Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
5-Lipoxygenase (5-LOX) has been implicated in the development and progression of lung, pancreatic and esophageal cancers. However, its role in
hepatocellular carcinoma
(
HCC
) remains unclear. This study aimed to explore the role of 5-LOX in the pathogenesis of
HCC
. The expression of 5-LOX was detected in human
HCC
, HepG2 cells and diethylnitrosamine (DEN)-induced rat
HCC
using immunohistochemistry (IHC) staining or reverse transcriptase-polymerase chain reaction. Apoptosis in rat
HCC
was evaluated by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) assay. Cell viability and apoptosis were determined in HepG2 cells by MTT assay and flow cytometry, respectively. IHC staining showed that the 5-LOX protein was highly expressed in human
HCC
, HepG2 cells and rat
HCC
, but not in the normal liver tissues. 5-LOX mRNA expression in human and rat
HCC
was also significantly increased compared to normal liver tissues.
Zileuton
, a 5-LOX inhibitor, reduced the nodule incidence and the mean number of nodules per nodule-bearing liver in DEN-induced rats. Further study using TUNEL assay showed that zileuton treatment induced apoptosis in the liver as the result of inhibition on 5-LOX levels. This result is consistent with our observation of significantly higher apoptotic indices in rats treated with DEN/zileuton, which were significantly higher compared to those from the control groups. In addition, zileuton reduced cell viability and induced apoptosis in a concentration- and time-dependent manner as detected using HepG2 cells in our in vitro analysis. In conclusion, 5-LOX is expressed in
HCC
, and the inhibition of 5-LOX blocks the development of
HCC
via the induction of apoptosis in tumor cells.
...
PMID:5-Lipoxygenase contributes to the progression of hepatocellular carcinoma. 2183 74